{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:30:12Z","timestamp":1773721812902,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobulin IgG1 used in antiangiogenic therapies due to its capacity to inhibit the interaction between vascular endothelial growth factor and its receptor. However, bevacizumab-based antiangiogenic therapy is not always effective due to poor treatment compliance associated to multiples administrations and drug resistance. In this work, we show a promising strategy of encapsulating bevacizumab to protect and deliver it, in a controlled manner, increasing the time between administrations and formulation shelf-life. Nanoencapsulation of bevacizumab represents a significant advance for selective antiangiogenic therapies since extracellular, cell surface and intracellular targets can be reached. The present study shows that bevacizumab-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles does not impair its native-like structure after encapsulation and fully retain the bioactivity, making this nanosystem a new paradigm for the improvement of angiogenic therapy.<\/jats:p>","DOI":"10.1038\/s41598-017-03959-4","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T13:21:51Z","timestamp":1497273711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-6175","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Sousa","sequence":"first","affiliation":[]},{"given":"Andrea","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Fonte","sequence":"additional","affiliation":[]},{"given":"In\u00eas Mendes","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Maria Teresa","family":"Neves-Petersen","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"3959_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"GJ Weiner","year":"2015","unstructured":"Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer \n                           15, 361\u2013370, doi:10.1038\/nrc3930 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"3959_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/19420862.2015.989042","volume":"7","author":"DM Ecker","year":"2015","unstructured":"Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal antibody market. mAbs \n                           7, 9\u201314, doi:10.4161\/19420862.2015.989042 (2015).","journal-title":"mAbs"},{"key":"3959_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. \n                           18, 4\u201325, doi:10.1210\/edrv.18.1.0287 (1997).","journal-title":"Endocr. Rev."},{"key":"3959_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1874364101206010054","volume":"6","author":"F Li","year":"2012","unstructured":"Li, F., Hurley, B., Liu, Y., Leonard, B. & Griffith, M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol. J. \n                           6, 54\u201358, doi:10.2174\/1874364101206010054 (2012).","journal-title":"Open Ophthalmol. J."},{"key":"3959_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","volume":"29","author":"M Abrishami","year":"2009","unstructured":"Abrishami, M. et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina \n                           29, 699\u2013703, doi:10.1097\/IAE.0b013e3181a2f42a (2009).","journal-title":"Retina"},{"key":"3959_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","volume":"16","author":"RT Penson","year":"2015","unstructured":"Penson, R. T. et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial. Lancet Oncol. \n                           16, 301\u2013311, doi:10.1016\/s1470-2045(15)70004-5 (2015).","journal-title":"Lancet Oncol."},{"key":"3959_CR7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12666","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Huang, Z., Zou, X. & Liu, T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. doi:10.18632\/oncotarget.12666 (2016).","journal-title":"Oncotarget"},{"key":"3959_CR8","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.18632\/oncotarget.1671","volume":"5","author":"P Mesange","year":"2014","unstructured":"Mesange, P. et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget \n                           5, 4709\u20134721, doi:10.18632\/oncotarget.1671 (2014).","journal-title":"Oncotarget"},{"key":"3959_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer \n                           8, 592\u2013603, doi:10.1038\/nrc2442 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"3959_CR10","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1021\/mp3005935","volume":"10","author":"AR Srinivasan","year":"2013","unstructured":"Srinivasan, A. R., Lakshmikuttyamma, A. & Shoyele, S. A. Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells. Mol. Pharm. \n                           10, 3275\u20133284, doi:10.1021\/mp3005935 (2013).","journal-title":"Mol. Pharm."},{"key":"3959_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cncr.22402","volume":"109","author":"RA Beckman","year":"2007","unstructured":"Beckman, R. A., Weiner, L. M. & Davis, H. M. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer \n                           109, 170\u2013179, doi:10.1002\/cncr.22402 (2007).","journal-title":"Cancer"},{"key":"3959_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejpb.2014.08.001","volume":"88","author":"D Schweizer","year":"2014","unstructured":"Schweizer, D., Serno, T. & Goepferich, A. Controlled release of therapeutic antibody formats. Eur. J. Pharm. Biopharm. \n                           88, 291\u2013309, doi:10.1016\/j.ejpb.2014.08.001 (2014).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"3959_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne, T. U., Eter, N., Holz, F. G. & Meyer, C. H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. \n                           146, 508\u2013512, doi:10.1016\/j.ajo.2008.05.036 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"3959_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","volume":"21","author":"KM Sampat","year":"2010","unstructured":"Sampat, K. M. & Garg, S. J. Complications of intravitreal injections. Curr. Opin. Ophthalmol. \n                           21, 178\u2013183, doi:10.1097\/ICU.0b013e328338679a (2010).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"3959_CR15","doi-asserted-by":"publisher","first-page":"255102","DOI":"10.1088\/0957-4484\/26\/25\/255102","volume":"26","author":"L Battaglia","year":"2015","unstructured":"Battaglia, L. et al. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology \n                           26, 255102, doi:10.1088\/0957-4484\/26\/25\/255102 (2015).","journal-title":"Nanotechnology"},{"key":"3959_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","volume":"50","author":"R Varshochian","year":"2013","unstructured":"Varshochian, R. et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur. J. Pharm. Sci. \n                           50, 341\u2013352, doi:10.1016\/j.ejps.2013.07.014 (2013).","journal-title":"Eur. J. Pharm. Sci."},{"key":"3959_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1517\/14712598.4.7.1029","volume":"4","author":"DW Grainger","year":"2004","unstructured":"Grainger, D. W. Controlled-release and local delivery of therapeutic antibodies. Expert Opin. Biol. Ther. \n                           4, 1029\u20131044, doi:10.1517\/14712598.4.7.1029 (2004).","journal-title":"Expert Opin. Biol. Ther."},{"key":"3959_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3980\/j.issn.2222-3959.2014.01.01","volume":"7","author":"Y Lu","year":"2014","unstructured":"Lu, Y. et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int. J. Ophthalmol \n                           7, 1\u20137, doi:10.3980\/j.issn.2222-3959.2014.01.01 (2014).","journal-title":"Int. J. Ophthalmol"},{"key":"3959_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release \n                           161, 505\u2013522, doi:10.1016\/j.jconrel.2012.01.043 (2012).","journal-title":"J. Control. Release"},{"key":"3959_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.peptides.2010.10.003","volume":"32","author":"SC Yadav","year":"2011","unstructured":"Yadav, S. C., Kumari, A. & Yadav, R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides \n                           32, 173\u2013187, doi:10.1016\/j.peptides.2010.10.003 (2011).","journal-title":"Peptides"},{"key":"3959_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4161\/biom.23246","volume":"2","author":"P Fonte","year":"2012","unstructured":"Fonte, P. et al. Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter \n                           2, 329\u2013339, doi:10.4161\/biom.23246 (2012).","journal-title":"Biomatter"},{"key":"3959_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(01)00944-9","volume":"233","author":"YN Konan","year":"2002","unstructured":"Konan, Y. N., Gurny, R. & All\u00e9mann, E. Preparation and characterization of sterile and freeze-dried sub-200\u2009nm nanoparticles. Int. J. Pharm. \n                           233, 239\u2013252, doi:10.1016\/S0378-5173(01)00944-9 (2002).","journal-title":"Int. J. Pharm."},{"key":"3959_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","volume":"2","author":"C Pinto Reis","year":"2006","unstructured":"Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J. & Veiga, F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine \n                           2, 8\u201321, doi:10.1016\/j.nano.2005.12.003 (2006).","journal-title":"Nanomedicine"},{"key":"3959_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2147\/IJN.S13532","volume":"5","author":"A Chwalibog","year":"2010","unstructured":"Chwalibog, A. et al. Visualization of interaction between inorganic nanoparticles and bacteria or fungi. Int. J. Nanomedicine \n                           5, 1085\u20131094, doi:10.2147\/ijn.s13532 (2010).","journal-title":"Int. J. Nanomedicine"},{"key":"3959_CR25","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1021\/bm5010383","volume":"15","author":"P Fonte","year":"2014","unstructured":"Fonte, P. et al. Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles. Biomacromolecules \n                           15, 3753\u20133765, doi:10.1021\/bm5010383 (2014).","journal-title":"Biomacromolecules"},{"key":"3959_CR26","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1021\/bi00465a022","volume":"29","author":"A Dong","year":"1990","unstructured":"Dong, A., Huang, P. & Caughey, W. S. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry \n                           29, 3303\u20133308, doi:10.1021\/bi00465a022 (1990).","journal-title":"Biochemistry"},{"key":"3959_CR27","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/jps.21736","volume":"98","author":"MJ Maltesen","year":"2009","unstructured":"Maltesen, M. J., Bjerregaard, S., Hovgaard, L. & Havelund, S. & Van De Weert, M. Analysis of insulin allostery in solution and solid state with FTIR. J. Pharm. Sci. \n                           98, 3265\u20133277, doi:10.1002\/jps.21736 (2009).","journal-title":"J. Pharm. Sci."},{"key":"3959_CR28","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.1016\/j.biomaterials.2014.07.026","volume":"35","author":"F Araujo","year":"2014","unstructured":"Araujo, F. et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials \n                           35, 9199\u20139207, doi:10.1016\/j.biomaterials.2014.07.026 (2014).","journal-title":"Biomaterials"},{"key":"3959_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nprot.2015.024","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang, H., Yang, S., Kong, J., Dong, A. & Yu, S. Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy. Nat. Protoc. \n                           10, 382\u2013396, doi:10.1038\/nprot.2015.024 (2015).","journal-title":"Nat. Protoc."},{"key":"3959_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","volume":"21","author":"I Bala","year":"2004","unstructured":"Bala, I., Hariharan, S. & Kumar, M. N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. \n                           21, 387\u2013422, doi:10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20 (2004).","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"3959_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12575-009-9008-x","volume":"11","author":"HP Erickson","year":"2009","unstructured":"Erickson, H. P. Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy. Biol. Proced. Online \n                           11, 32\u201351, doi:10.1007\/s12575-009-9008-x (2009).","journal-title":"Biol. Proced. Online"},{"key":"3959_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/HAB-2011-0244","volume":"20","author":"S Kaja","year":"2011","unstructured":"Kaja, S. et al. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin\u2122) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum. Antibodies \n                           20, 95\u2013101, doi:10.3233\/HAB-2011-0244 (2011).","journal-title":"Hum. Antibodies"},{"key":"3959_CR33","doi-asserted-by":"crossref","unstructured":"Shah, R., Eldridge, D., Palombo, E. & Harding, I. Lipid Nanoparticles: Production, Characterization and Stability. 1 edn, Vol. 1 (Springer International Publishing, 2015).","DOI":"10.1007\/978-3-319-10711-0"},{"key":"3959_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1208\/s12249-010-9382-3","volume":"11","author":"PV Date","year":"2010","unstructured":"Date, P. V., Samad, A. & Devarajan, P. V. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech \n                           11, 304\u2013313, doi:10.1208\/s12249-010-9382-3 (2010).","journal-title":"AAPS PharmSciTech"},{"key":"3959_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"S Mitragotri","year":"2014","unstructured":"Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. \n                           13, 655\u2013672, doi:10.1038\/nrd4363 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3959_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2147\/IJN.S18905","volume":"6","author":"R Dinarvand","year":"2011","unstructured":"Dinarvand, R., Sepehri, N., Manoochehri, S., Rouhani, H. & Atyabi, F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int. J. Nanomedicine \n                           6, 877\u2013895, doi:10.2147\/ijn.s18905 (2011).","journal-title":"Int. J. Nanomedicine"},{"key":"3959_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/pharmaceutics7020074","volume":"7","author":"A Vilella","year":"2015","unstructured":"Vilella, A. et al. Endocytosis of nanomedicines: the case of glycopeptide engineered PLGA nanoparticles. Pharmaceutics \n                           7, 74\u201389, doi:10.3390\/pharmaceutics7020074 (2015).","journal-title":"Pharmaceutics"},{"key":"3959_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","volume":"74","author":"JA Mindell","year":"2012","unstructured":"Mindell, J. A. Lysosomal acidification mechanisms. Annu. Rev. Physiol. \n                           74, 69\u201386, doi:10.1146\/annurev-physiol-012110-142317 (2012).","journal-title":"Annu. Rev. Physiol."},{"key":"3959_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbsr.2016.04.002","volume":"9","author":"MH Jazayeri","year":"2016","unstructured":"Jazayeri, M. H., Amani, H., Pourfatollah, A. A., Pazoki-Toroudi, H. & Sedighimoghaddam, B. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sens. Biosensing Res \n                           9, 17\u201322, doi:10.1016\/j.sbsr.2016.04.002 (2016).","journal-title":"Sens. Biosensing Res"},{"key":"3959_CR40","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1158\/1535-7163.MCT-06-0159","volume":"6","author":"GN Chiu","year":"2007","unstructured":"Chiu, G. N. et al. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol. Cancer Ther. \n                           6, 844\u2013855, doi:10.1158\/1535-7163.mct-06-0159 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"3959_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1081\/DDC-43985","volume":"31","author":"AJ Thote","year":"2005","unstructured":"Thote, A. J., Chappell, J. T. Jr., Gupta, R. B. & Kumar, R. Reduction in the initial-burst release by surface crosslinking of PLGA microparticles containing hydrophilic or hydrophobic drugs. Drug Dev. Ind. Pharm \n                           31, 43\u201357, doi:10.1081\/ddc-43985 (2005).","journal-title":"Drug Dev. Ind. Pharm"},{"key":"3959_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/toxsci\/52.1.101","volume":"52","author":"J Mordenti","year":"1999","unstructured":"Mordenti, J. et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol. Sci. \n                           52, 101\u2013106, doi:10.1093\/toxsci\/52.1.101 (1999).","journal-title":"Toxicol. Sci."},{"key":"3959_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","volume":"38","author":"A Hawe","year":"2009","unstructured":"Hawe, A., Kasper, J. C., Friess, W. & Jiskoot, W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur. J. Pharm. Sci. \n                           38, 79\u201387, doi:10.1016\/j.ejps.2009.06.001 (2009).","journal-title":"Eur. J. Pharm. Sci."},{"key":"3959_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.2042-7158.1997.tb00235.x","volume":"3","author":"HR Costantino","year":"1997","unstructured":"Costantino, H. R., Andya, J. D., Shire, S. J. & Hsu, C. C. Fourier-transform infrared spectroscopic analysis of the secondary structure of recombinant humanized immunoglobulin G. Pharm. Pharmacol. Commun \n                           3, 121\u2013128, doi:10.1111\/j.2042-7158.1997.tb00235.x (1997).","journal-title":"Pharm. Pharmacol. Commun"},{"key":"3959_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0939-6411(98)00005-8","volume":"45","author":"JF Carpenter","year":"1998","unstructured":"Carpenter, J. F., Prestrelski, S. J. & Dong, A. Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur. J. Pharm. Biopharm. \n                           45, 231\u2013238, doi:10.1016\/S0939-6411(98)00005-8 (1998).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"3959_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jps.2600840407","volume":"84","author":"A Dong","year":"1995","unstructured":"Dong, A., Prestrelski, S. J., Allison, S. D. & Carpenter, J. F. Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J. Pharm. Sci. \n                           84, 415\u2013424, doi:10.1002\/jps.2600840407 (1995).","journal-title":"J. Pharm. Sci."},{"key":"3959_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbapap.2005.06.005","volume":"1751","author":"SM Kelly","year":"2005","unstructured":"Kelly, S. M., Jess, T. J. & Price, N. C. How to study proteins by circular dichroism. Biochim. Biophys. Acta \n                           1751, 119\u2013139, doi:10.1016\/j.bbapap.2005.06.005 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"3959_CR48","doi-asserted-by":"publisher","first-page":"12391","DOI":"10.1073\/pnas.97.23.12391","volume":"97","author":"RL Baldwin","year":"2000","unstructured":"Baldwin, R. L. & Zimm, B. H. Are denatured proteins ever random coils? Proc. Natl. Acad. Sci. USA \n                           97, 12391\u201312392, doi:10.1073\/pnas.97.23.12391 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3959_CR49","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1016\/S1359-0278(96)00046-6","volume":"1","author":"LJ Smith","year":"1996","unstructured":"Smith, L. J., Fiebig, K. M., Schwalbe, H. & Dobson, C. M. The concept of a random coil: Residual structure in peptides and denatured proteins. Fold. Des. \n                           1, R95\u2013R106, doi:10.1016\/S1359-0278(96)00046-6 (1996).","journal-title":"Fold. Des."},{"key":"3959_CR50","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0006-3495(00)76602-1","volume":"78","author":"AW Vermeer","year":"2000","unstructured":"Vermeer, A. W. & Norde, W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys. J. \n                           78, 394\u2013404, doi:10.1016\/S0006-3495(00)76602-1 (2000).","journal-title":"Biophys. J."},{"key":"3959_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jps.23354","volume":"102","author":"SA Abbas","year":"2013","unstructured":"Abbas, S. A., Gaspar, G., Sharma, V. K., Patapoff, T. W. & Kalonia, D. S. Application of second-derivative fluorescence spectroscopy to monitor subtle changes in a monoclonal antibody structure. J. Pharm. Sci. \n                           102, 52\u201361, doi:10.1002\/jps.23354 (2013).","journal-title":"J. Pharm. Sci."},{"key":"3959_CR52","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1021\/mp400487f","volume":"10","author":"S K.Yandrapu","year":"2013","unstructured":"K.Yandrapu, S., Upadhyay, A. K., Petrash, J. M. & Kompella, U. B. Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab. Mol. Pharm. \n                           10, 4676\u20134686, doi:10.1021\/mp400487f (2013).","journal-title":"Mol. Pharm."},{"key":"3959_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","volume":"247","author":"YS Han","year":"2009","unstructured":"Han, Y. S., Lee, J. E., Jung, J. W. & Lee, J. S. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. \n                           247, 541\u2013548, doi:10.1007\/s00417-008-0976-3 (2009).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"3959_CR54","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpba.2016.03.042","volume":"125","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies. J. Pharm. Biomed. Anal. \n                           125, 212\u2013218, doi:10.1016\/j.jpba.2016.03.042 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"3959_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H.-P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. \n                           3, 391\u2013400, doi:10.1038\/nrd1381 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3959_CR56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang, Y., Fei, D., Vanderlaan, M. & Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis \n                           7, 335\u2013345, doi:10.1007\/s10456-004-8272-2 (2004).","journal-title":"Angiogenesis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03959-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03959-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03959-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:29:37Z","timestamp":1671773377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03959-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["3959"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-03959-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"assertion":[{"value":"12 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3736"}}